Alkem Laboratories Limited — Q4 FY26
Alkem delivered a strong Q4 FY26 with revenue of ₹3,633 crore (+14.6% YoY) and EBITDA of ₹517.4 crore (+32.2% YoY), resulting in an EBITDA margin of 14.24% (+184 bps YoY).
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
67%Questions answered2Evaded / deflected12Questions auditedContradictedNumbers vs filing
Evasive
High priority
Strategic levers for FY27 to expand domestic formulation leadership and manage pricing risks.
Asked by Sukrit Dartil, Eyesight Ventrade Private Limited
Management dismissed the question by saying no specific strategy exists, then gave generic comments.
denied existence of specific strategyvague reference to past strategy
Read the exchange
Question
what type of strategic levers are you prioritizing in FY 2627 to expand Alam's domestic formulation leadership and accelerate growth in chronic and manage risk from regulatory pricing pressures and global competition.
Sandeep Singh (MD) and Vikas (President)
I think there is no strategic liver for 26 27. Every year we don't have a strategic liver. We are continuing on whatever strategy we had decided last few years and that's paying good yield.
Partial answer
High priority
Capital allocation and risk management frameworks for FY27 balancing dividends, R&D, and forex hedging.
Asked by Sukrit Dartil, Eyesight Ventrade Private Limited
Provided some details on hedging and dividend policy but avoided quantifying cost impact.
no specific number for impactqualitative only
Read the exchange
Question
What type of capital allocation and risk management frameworks have been applied in 2627 to balance dividend payouts with funding for R&D in biosimilars and specialty drugs. any hedge against forex and raw material volatility and any liquidity buffers.
Nath Agarwal (CFO)
we have a forex policy and we generally cover 80% or we hedge 80% of our forex exposure in terms of raw material prices. ... we don't foresee any further investment into acquisitions at least for say next 12 months.
Answered
High priority
India business growth outlook and trade generic vs branded generic performance in FY26.
Asked by Niha Manpurya, Bank of America
Provided specific growth guidance relative to market and gave trade generic growth number.
Read the exchange
Question
given that we have grown this year at close to about 10%. How should we think about growth going forward? Should we assume that growth improves further? and if you could also give us some color into how the trade generic business grow in FI26 versus debranded.
Vikas (President)
I have always maintained that we will grow 100 to 150 basis points higher than the market. ... trade generic this year the growth has been lesser ... close to around 4.3% on an annualized basis.
Evasive
High priority
Impact of cost headwinds on margin improvement guidance of 100 bps per year.
Asked by Niha Manpurya, Bank of America
Management backtracked on margin guidance citing geopolitical uncertainty, offered no specific target.
no commitmentdeferred clarity to H2
Read the exchange
Question
how should we think about the margin improvement guidance that we mentioned in the past that you know we should see 100 basis points margin improvement every year. would it be possible for us to deliver on that or do you think the best case at the moment would be for us to be able to maintain the FI26 margins?
Vikas (President)
when we had given the guidance of 100 basis points improvement maybe every year that is more on a more stable and a like to like period ... in the current scenario it looks like whatever we have achieved in the current year, we should be pretty much in line with at least that.
Answered
Medium priority
Sustainability of Q4 operating cost increases in R&D and other expenses.
Asked by Niha Manpurya, Bank of America
Provided R&D range and explained Q4 spike; gave other expenses growth estimate of 7-8%.
Read the exchange
Question
I see that R&D is increased materially. We've also seen an increase in other expenses. So any color on you know is this a sustainable base of cost that we should assume? So I mean R&D what should be the range as well as the other expenses?
Vikas (President) and Nath Agarwal (CFO)
in Q4 even last year we had 5% of our revenue as a R&D spend and this year it has been around six and a half% but if you look at the annual spend it'll be within the range of 4 to 5% only.
Partial answer
Medium priority
Regulatory launch timeline for denosumab portfolio in the US.
Asked by Sepumar, Clintis Research Solutions
Gave a rough timeline but no commitment; mentioned lack of basket as uncertainty.
vague timelineno specific date
Read the exchange
Question
Could management provide an regulatory launch timeline for the Dennis portfolio? Currently, I know we are in the FDN activity. So how should we think about the approval and launch timeline for prolifers in the US?
Sandeep Singh (MD)
we are under approval. I think with this I think if we are good maybe by next quarter I mean next next year's first quarter. So there's still some time. And second thing keep in mind that we don't have a basket yet.
Answered
High priority
FY27 growth estimates by business line and margin range considering currency and costs.
Asked by Kunal Damesha, McQuary
Provided specific growth guidance for each segment and margin range of 20-21%.
Read the exchange
Question
what are your estimates or internal budget for growth in our various line of businesses for FI27 and on margin ... where do you see the FI27 margin range to?
Vikas (President)
domestic I have already called out that we should be 100 250 basis points higher than the market ... US market we are looking at a high singledigit margin ... RO markets we've looked at a higher teams kind of market growth ... we should be within the range of 20 to 21%.
Answered
Medium priority
Medtech contribution and Occlud acquisition timeline.
Asked by Kunal Damesha, McQuary
Provided current contribution and expected closing timeline.
Read the exchange
Question
what is the current contribution from the medtech and when would the okloc acquisition be concluded and then when will we start seeing those numbers in Alkem's numbers?
Sandeep Singh (MD)
contribution in less than a percentage right now met is very small and then by when the deal will close maybe in like in 45 to 60 days it will get complete.
Partial answer
Medium priority
Trade generic profitability relative to other segments.
Asked by Kunal Damesha, McQuary
Gave directional improvement but no specific margin comparison.
no specific margin numberqualitative only
Read the exchange
Question
where would the trade generic profitability would fit in from the chronological order perspective?
Vikas (President)
we have improved in the last few years and now even trade generic is not very far from our corporate margins so you know that has been our intent.
Partial answer
Medium priority
Revenue and cost of US enzyme/biological plant in Q4.
Asked by Abdul Kadar Puranwalla, ICICI Securities
Provided qualitative status but no Q4 revenue or cost figures.
no specific revenue or cost numbersqualitative only
Read the exchange
Question
with regards to the revenue and the cost of enzyme and the US biologic plant what you have started. So if you could highlight that the cost as well as the revenue in Q4.
Sandeep Singh (MD)
India is around is in break even much more than break even. We are in early sing double digits you can say teens bita US we will lose money of course because that takes time to ramp up.
Answered
High priority
CEO succession plan and organizational structure post-Vikas departure.
Asked by Tushar Man, Motila Losal Financial Services
Provided clear plan for CEO search and timeline.
Read the exchange
Question
are we going to look for a new CEO or and now that tech is also there where of course business heads are correct so if you could sort of give a overall CXO level changes that would happen or any new person coming up?
Sandeep Singh (MD)
we will look for a CEO. We have engaged with the top three global header for this and that would be in place. It would take few months but business will go on because promoters are completely involved.
Answered
Medium priority
Launch timeline for Tolapin in US and expected competition.
Asked by Rahul Juni, IFL Securities Limited
Provided specific launch timeline and competitive landscape assessment.
Read the exchange
Question
on the US business we had received approval for Tolapin. So when could be a launch for the product and when you launch do you think the market would still be limited competition?
Vikas (President)
our expected launch is around September or October ... it's a limited player launch you know it's not as crowded as some of the other product categories.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Trade generic growth 4.3% in FY26 | 4.3% | 14.6% | Understated vs filing |
| EBITDA margin range 20-21% for FY27 | 20.5% | 14% | Overstated vs filing |
| US growth high single-digit on dollar basis | 8% | 14.6% | Understated vs filing |
| CDMO revenue from US less than 100 cr last year | ₹100 cr | ₹3,603 cr | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.